viewLancor Scientific

Lancor Scientific on the commercial push as it advances its tumour trace product

Lancor Scientific's CEO Aamir Butt and sales director Rory Lavelle update Proactive London's Andrew Scott on developments as news broke that they've gained access to a cancer research laboratory in Austria. 

''Having access to that kind of capability means we can now make the bold claim that by the end of 2019 we'll have a device capable of multiple cancers'', Butt says.

''What we're aiming to do is make cancer detection available for everyone, everywhere'', he adds.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives...



Lancor Scientific to have its screening device approved for six cancers by March

Lancor Scientific's Roland Schlesinger updates Proactive London's Andrew Scott on latest developments with their cancer screening device. He says they've already got one cancer device approved with five more soon to follow. ''We're in the process of moving towards mass production...

on 22/5/19

2 min read